Intelligence · Clinical Development
Pipeline search results
Programs matching “anlotinib” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 20 pipeline programs matching "anlotinib" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
AK105 and anlotinib
The First People's Hospital of Lianyungang
Cervical Cancer
1 trial -
Anlotinib
The First People's Hospital of Lianyungang
Non-Small-Cell Lung Cancer
1 trial -
Anlotinib Hydrochloride
The First People's Hospital of Lianyungang
Effect of Drugs
1 trial -
Anlotinib and Sintilimab injection
The First People's Hospital of Lianyungang
Advanced Hepatocellular Carcinoma
1 trial -
Anlotinib combined Docetaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Anlotinib plus Pemetrexed
Henan Provincial People's Hospital
Non-squamous Cell Non-Small Cell Lung Cancer
1 trial -
Anlotinib+ Liposomal Doxorubicin
The First People's Hospital of Lianyungang
Sarcoma
1 trial -
Experimental: tislelizumab+anlotinib
The First People's Hospital of Lianyungang
Thymic Carcinoma
1 trial -
Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor
The First People's Hospital of Lianyungang
HER2-Negative Breast Cancer
1 trial -
anlotinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sarcoma, Soft Tissue
1 trial -
anlotinib
Fudan University
Extensive-stage Small Cell Lung Cancer
1 trial -
anlotinib +TQB2450 + Oxaliplatin+S-1
The First People's Hospital of Lianyungang
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
1 trial -
anlotinib combined with penpulimab
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
anlotinib+TQB2450+nab-paclitaxel+cisplatin
The First People's Hospital of Lianyungang
Advanced Biliary Tract Cancer
1 trial -
osimertinib mesylate tablets and anlotinib hydrochloride capsules
The First People's Hospital of Lianyungang
Non Small Cell Lung Cancer
1 trial -
Anlotinib hydrochloride,Penpulimab
The First People's Hospital of Lianyungang
Colorectal Cancer
1 trial -
Realgar-Indigo Naturalis Formulation Combined with Anlotinib
The First People's Hospital of Lianyungang
Platinum-resistant Ovarian Cancer (PROC)
1 trial -
Anlotinib Hydrochloride
The First People's Hospital of Lianyungang
Non-Small-Cell Lung
1 trial -
Anlotinib hydrochloride
The First People's Hospital of Lianyungang
Non-Small-Cell Lung Cancer
2 trials -
Hydrochloride anlotinib
Zhongnan Hospital
Uterine Cervical Neoplasms
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.